Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EGFR-ILs-dox
- Development stage
- Unknown
- Lead developer
- Swiss Group for Clinical Cancer Research
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
anti-EGFR-ILs-dox is a targeted nanocontainer drug developed for the treatment of EGFR-overexpressing malignancies. It consists of pegylated liposomes containing doxorubicin, with anti-EGFR antibody fragments (derived from cetuximab) covalently inserted into the lipid bilayer. This immunoliposomal delivery system is designed to enhance the therapeutic index of doxorubicin by increasing drug concentration at the tumor site and facilitating intracellular delivery via receptor-mediated endocytosis, potentially overcoming multidrug resistance. While it showed a manageable safety profile in Phase I and II trials, a Phase II study in triple-negative breast cancer (TNBC) failed to meet its primary endpoint of progression-free survival, leading to the discontinuation of development for that specific indication. It has also been investigated in glioblastoma.
- Other names
- anti-EGFR immunoliposomal doxorubicindoxorubicin-loaded anti-EGFR immunoliposomesanti-EGFR targeted nanocontainer drug
02
Targets
Beyond the preview
Go deeper on anti-EGFR-ILs-dox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EGFR-ILs-dox.